Reisine T, Kong H, Raynor K, Yano H, Takeda J, Yasuda K, Bell G I
Department of Pharmacology, University of Pennsylvania School of Medicine, Philadelphia 19104.
Mol Pharmacol. 1993 Nov;44(5):1016-20.
The diverse biological actions of somatostatin (SRIF) are mediated by a family of receptors, of which five have been cloned and characterized. One of the SRIF receptor subtypes, SSTR2, has been shown to exist in two forms. SSTR2A and SSTR2B are 369 and 346 amino acids in size, respectively, and differ in length and amino acid sequence in their intracellularly located carboxyl termini. SSTR2A and SSTR2B are generated by alternative splicing of SSTR2 mRNA. We previously characterized mouse SSTR2A and showed that it could be distinguished from other cloned SRIF receptor subtypes by its high affinity for MK-678 and its lack of coupling to adenylyl cyclase. To determine whether the properties of mouse SSTR2A and SSTR2B differ, we have expressed both in COS-7 cells and characterized their ligand-binding properties and ability to couple to adenylyl cyclase. The two receptors exhibited similar affinities for a number of SSTR2-selective agonists such as MK-678. Pretreatment with SRIF of COS-7 cells expressing each receptor reduced high affinity agonist binding to both SSTR2A and SSTR2B, indicating that both receptors can be regulated. Furthermore, agonist binding to both receptors was reduced by GTP analogs and Na+, indicating that they both associate with G proteins. As shown previously, SSTR2A could not mediate SRIF inhibition of forskolin-stimulated cAMP formation. In contrast, SSTR2B was coupled to adenylyl cyclase and was able to mediate SRIF inhibition of forskolin-stimulated cAMP formation. Thus, SSTR2A and SSTR2B differ in their ability to couple to adenylyl cyclase. Because SSTR2A and SSTR2B differ only in the length and amino acid sequence of their carboxyl termini, these findings imply that the carboxyl-terminal 15 residues of SSTR2B may be involved in coupling this receptor to adenylyl cyclase.
生长抑素(SRIF)的多种生物学作用是由一类受体介导的,其中五种已被克隆并鉴定。SRIF受体亚型之一SSTR2已被证明以两种形式存在。SSTR2A和SSTR2B的大小分别为369和346个氨基酸,它们在细胞内羧基末端的长度和氨基酸序列不同。SSTR2A和SSTR2B是由SSTR2 mRNA的可变剪接产生的。我们之前对小鼠SSTR2A进行了鉴定,结果表明它对MK-678具有高亲和力且不与腺苷酸环化酶偶联,这使其有别于其他克隆的SRIF受体亚型。为了确定小鼠SSTR2A和SSTR2B的特性是否不同,我们在COS-7细胞中表达了这两种受体,并对它们的配体结合特性以及与腺苷酸环化酶偶联的能力进行了鉴定。这两种受体对多种SSTR2选择性激动剂(如MK-678)表现出相似的亲和力。用SRIF预处理表达每种受体的COS-7细胞,可降低高亲和力激动剂与SSTR2A和SSTR2B的结合,这表明两种受体均可被调节。此外,GTP类似物和Na+可降低激动剂与两种受体的结合,这表明它们都与G蛋白相关。如之前所示,SSTR2A不能介导SRIF对福斯高林刺激的cAMP形成的抑制作用。相比之下,SSTR2B与腺苷酸环化酶偶联,并且能够介导SRIF对福斯高林刺激的cAMP形成的抑制作用。因此,SSTR2A和SSTR2B在与腺苷酸环化酶偶联的能力上存在差异。由于SSTR2A和SSTR2B仅在其羧基末端的长度和氨基酸序列上有所不同,这些发现表明SSTR2B的羧基末端15个残基可能参与了该受体与腺苷酸环化酶的偶联。